Recent

% | $
Quotes you view appear here for quick access.

Dendreon Corporation Message Board

  • dberger98 dberger98 Apr 14, 2010 6:35 PM Flag

    Don't tell ne Lucy Lu gets paid for this

    A downgrade that raises the price target raise and forecasts a 20% bump on approval? I call that an "upgrade!"

    Citigroup downgraded shares of Dendreon from buy to hold citing valuation. The company is waiting for regulatory approval for its new prostate cancer drug and analyst Lucy Lu wrote in her report that the shares are currently "priced to perfection". With the downgrade, Citigroup raised its price target to $40 per share and noted that the price could climb to $50 per share if the drug is approved.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
DNDN
0.1270.000(0.00%)Nov 18 4:00 PMEST